Compared to AChR-MG, CD20 expression was reduced in total CD20+ B cells, naïve B cells, total DN B cells, DN2, DN3, and DN4 B cells in rituximab-naïve MuSK-MG subjects, whereas CD20 expression was not significantly different between rituximab-treated and AChR-MG subjects. Here, MUSK is linked to myasthenia gravis.